United States Securities and Exchange Commission
                    Washington, D. C. 20549

                          FORM 10-QSB

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                     EXCHANGE ACT OF 1934

            For the quarterly period September 30, 2005

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

               For the transition period from to

                 Commission File No. 000-32393

                          eGene, Inc.
                          -----------
(Exact Name of Small Business Issuer as Specified in its Charter)

       NEVADA                                        87-0645507
       ------                                        ----------
(State or Other Jurisdiction of                 (I.R.S. Employer I.D. No.)
 incorporation or organization)


             17841 Fitch, Irvine, California 92614
             -------------------------------------
           (Address of Principal Executive Offices)

           Issuer's Telephone Number: (949) 250-8686

Check whether the Registrant (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter Period that the Registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes [X] No
[ ]

       APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
          PROCEEDINGS DURING THE PRECEDING FIVE YEARS

                        Not applicable.

Check whether the Registrant filed all documents and reports required to be
filed by Section 12, 13 or 15(d) of the Exchange Act after the distribution of
securities under a plan confirmed by a court. Yes   No
                                                 ---  ---

Indicate by check mark whether the Registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).  Yes     No X
                                        ---    ---

             APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the Registrant's classes
of common stock, as of the latest practicable date.

The number of our outstanding shares of common stock as of September 30, 2005,
was 13,439,351 (actual); however, assuming all stockholders of BioCal
Technology, Inc., a California corporation ("BioCal"), who did not perfect
dissenters' rights in the merger of our wholly-owned subsidiary that was
formed for the sole purpose of merging with and into BioCal submit their
BioCal shares for exchange under that Agreement and Plan of Merger and by
which BioCal became a wholly-owned subsidiary of ours, then there will be
15,624,188 outstanding shares.

Transitional Small Business Disclosure Format (Check One): Yes X  No
                                                              ---   ---
<PAGE>                          1
                           eGene, Inc.

                        Table of Contents
                                                                         Page

PART I    FINANCIAL INFORMATION

Item 1.   Financial Statements
          Condensed Consolidated Balance Sheet as of September 30, 2005    3

          Condensed Consolidated Statements of Operations for the
          Three and Nine Months Ended September 30, 2005 and 2004          4

          Condensed Consolidated Statements of Cash Flows for the
          Three and Nine Months Ended September 30, 2005 and 2004          5

          Notes to Unaudited Condensed Consolidated Financial Statements   6

Item 2.   Management's Discussion and Analysis of Financial Condition and
          Results of Operations                                            9

Item 3.   Controls and Procedures                                         13

PART II   OTHER INFORMATION

Item 1.   Legal Proceedings                                               15

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds     15

Item 3.   Defaults upon Senior Securities                                 15

Item 4.   Submission of Matters to a Vote of Security Holders             15

Item 5.   Other Information                                               15

Item 6.   Exhibits                                                        15

SIGNATURES
<PAGE>                          2
                PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

The Financial Statements of the Registrant required to be filed with this 10-
QSB Quarterly Report were prepared by management, and commence on the
following page, together with Related Notes. In the opinion of management, the
Financial Statements fairly present the financial condition of the Registrant.


               CONDENSED CONSOLIDATED BALANCE SHEET
                           (unaudited)
                            30-Sep-05
                              ASSETS
Current Assets
      Cash                                         $  250,186
      Accounts Receivable                             104,683
      Inventory                                       312,908
                                                   ----------
   Total Current Assets                               667,777
   Fixed Assets
      Computer Equipment                               42,994
      Equipment and Machinery                          42,858
      Furniture and Fixtures                           18,413
      Tooling                                         234,347
      Less Accumulated Depreciation                   (90,794)
                                                   ----------
   Total Fixed Assets                                 247,818
   Other Assets
      Deferred Patent and Amortizable Cost            301,401
      Deposits                                         23,903
                                                   ----------
   Total Other Assets                                 325,304
                                                   ----------
TOTAL ASSETS                                        1,240,899
                                                   ==========
             LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities
   Current Liabilities
      Accounts Payable                             $  124,084
      Accrued Payroll & Payroll Liabilities           277,466
      Accrued Vacation Pay                             32,851
      Warranty Accrual                                 43,645
      Other Current Liabilities                            50
                                                   ----------
   Total Current Liabilities                          478,096
                                                   ----------
   Total Liabilities                                  478,096

   Stockholders' Equity
      Common Stock                                     15,624
      Additional Paid in Capital                    4,711,457
      Deposit for Future Stock Subscription           400,000
      Deficit Accumulated during Development Stage (4,364,278)
                                                   ----------
   Total Stockholders' Equity                         762,803
                                                   ----------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY          1,240,899
                                                   ==========
See accompanying notes to the condensed consolidated financial statements.
<PAGE>                          3
                           eGene, Inc.
          CONDENSED CONSOLIDATED STATEMENTS OF OPERATION
                           (unaudited)
                                                                        From
                                                                     Inception
                               Three     Three     Nine      Nine     3/1/1999
                               Months    Months    Months    Months
                               Ended     Ended     Ended     Ended       To
                             9/30/2005 9/30/2004 9/30/2005 9/30/2004 9/30/2005

Revenues
   Sales                  $ 223,555 $  283,026 $ 707,695 $ 542,718 $1,604,704
   Services                       -          -     5,420         -    128,062
                          --------- ---------- --------- --------- ----------
Total Revenues              223,555    283,026   713,115   542,718  1,732,766
                          --------- ---------- --------- --------- ----------
Cost of Goods Sold          107,810    117,327   356,402   257,812    881,643
                          --------- ---------- --------- --------- ----------
Gross Profit                115,745    165,699   356,713   284,906    851,123
                          --------- ---------- --------- --------- ----------
Expenses
      Accounting & Audit      3,785      2,000    30,734    12,663     64,740
      Amortization &
       Depreciation           7,685      5,560    22,522    24,302    101,338
      General Office
       Expenses               3,829      5,746     8,082    13,354    103,359
      Insurance              23,798     23,083    56,095    43,542    151,361
      Legal Expenses         19,374     41,964    32,807    50,847     43,419
      Manufacturing &
       Production            10,858      2,535    18,386    18,227     18,386
      Marketing & Sales      21,461     18,389    62,774    43,529    307,960
      Office Equipment          596      2,390     3,325     6,137     17,171
      Office Supplies         1,987      2,065     6,934    10,038      6,934
      Postage and Delivery    1,222      2,830     7,191     5,124     15,462
      Professional Fees      11,742     52,333    31,801    52,333    280,947
      Rent - Building        22,222     18,080    65,926    30,080    171,844
      Research &
       Development           14,003     82,319    46,806   347,334  1,122,069
      Salaries, Wages &
       Taxes                178,152    153,513   651,307   474,877  2,802,003
      Telephone & Utilities   6,033      5,117    15,887    12,698     75,186
      Property and State
       Taxes                      -          -     1,236     1,286      1,236
                          --------- ---------- --------- --------- ----------
Total Expenses              326,747    417,924 1,061,813 1,146,371  5,283,415
                          --------- ---------- --------- --------- ----------
Net Operating Loss         (211,002)  (252,225) (705,100) (861,465)(4,432,292)
                          --------- ---------- --------- --------- ----------
Net Other Income              1,219      2,864     4,369     4,070     63,373
                          --------- ---------- --------- --------- ----------
Net Loss Before Income
Taxes                      (209,783)  (249,361) (700,731) (857,395)(4,368,919)
                          --------- ---------- --------- --------- ----------
Current Year Provision
for Income Taxes                  -          -         -         -          -
                          --------- ---------- --------- --------- ----------
Net Loss                   (209,783)  (249,361) (700,731) (857,395)(4,368,919)
                          --------- ---------- --------- --------- ----------
Loss Per Share                (0.01)     (0.02)    (0.04)    (0.08)     (0.62)
                          --------- ---------- --------- --------- ----------
Average Shares
Outstanding             15,624,188 12,833,305 15,584,446 11,197,406 7,058,009

See accompanying notes to the condensed consolidated financial statements.
<PAGE>                          4
                           eGene, Inc.
          CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                           (unaudited)

                                                                        From
                                                                     Inception
                               Three     Three     Nine      Nine     3/1/1999
                               Months    Months    Months    Months
                               Ended     Ended     Ended     Ended       To
                             9/30/2005 9/30/2004 9/30/2005 9/30/2004 9/30/2005

CASH FLOWS FROM OPERATING
ACTIVITIES
   Net Income (Loss)      $(209,783)$(249,361)$(700,731)$(857,395)$(4,368,919)
   Adjustments to Net Income

   Amortization               1,301       231     3,905     1,460      10,545

   Stock Issued for Services                                           72,177

   Depreciation               6,384     5,329    18,617    33,747      75,367
   (Increase) decrease in
     current assets           1,973  (388,749)   86,365  (430,485)   (424,292)
   Increase (decrease) in
     current liabilities    (25,864) (190,344)   65,166    31,006     483,075
                          --------- --------- --------- ---------  ----------
Net cash provided (used)
by operating activities    (225,989) (822,894) (526,678)(1,221,667)(4,152,047)
                          --------- --------- --------- ---------- ----------
CASH FLOWS FROM INVESTING ACTIVITIES
   Purchase of Fixed
    Assets                   (2,657)        -    (3,755)   (19,191)  (332,248)
   (Increase) decrease
    in other assets          (5,051)  (29,550)  (31,723)   (60,766)  (335,849)
                          --------- --------- --------- ---------- ----------
Net cash provided (used)
by investing activities      (7,708)  (29,550)  (35,478)   (79,957)  (668,097)
                          --------- --------- --------- ---------- ----------
CASH FLOWS FROM FINANCING ACTIVITIES
   Capital Stock Issued
   / Deposit for Future
   Stock Subscriptions      400,000 1,521,956   410,583  1,860,198  5,070,330
                          --------- --------- --------- ---------- ----------
Net Increase (Decrease)
in Cash                     166,303   669,512  (151,573)   558,574    250,186

Cash at beginning of period  83,883   164,254   401,759    275,192          -
                          --------- --------- --------- ---------- ----------
Cash at end of period       250,186   833,766   250,186    833,766    250,186
                          ========= ========= ========= ========== ==========
Supplemental disclosure of
   Interest paid                  -         -         -          -
   Income tax paid                -         -       800        800
   Item not affecting cash        -         -         -          -

 See accompanying notes to the condensed consolidated financial statements.


<PAGE>                          5
                           eGene, Inc.

      NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                         September 30, 2005

                          (Unaudited)

1. ORGANIZATION AND INTERIM FINANCIAL STATEMENTS

Effective July 13, 2004, Centroid Consolidated Mines Co., (Centroid), which
changed its name to eGene, Inc. (eGene), completed a merger with BioCal
Technology, Inc., (BioCal) a private California corporation in the business of
developing, manufacturing, and marketing genetic analyzer systems and reagents
for the global genetic testing market. In conjunction with our merger, we
raised $1.6 million in private funding. We had no material business operations
at the time that we acquired BioCal Technology.

The merger caused BioCal to become a wholly-owned subsidiary of eGene, a
dormant, publicly held Nevada corporation. The terms of the merger provided
that eGene exchange one of its shares of common stock for every three
outstanding shares of common stock of BioCal and one of its options to acquire
shares of common stock of eGene for every three outstanding options to acquire
common stock of BioCal. The combination was a "reverse merge". The transaction
was accounted for as a recapitalization of BioCal wherein the net assets are
brought forward at their net book value with no goodwill recognized, and the
pre-merger financial statements of BioCal became the historical financial
statements of the combined company.

The directors and executive officers of BioCal subsequently became the
directors and officers of the reorganized entity. Our Centroid Nevada
corporation has changed its name to eGene, Inc.

The accompanying unaudited consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Form 10-QSB and
Article 10 of Regulation S-X of the Securities and Exchange Commission
("SEC"). Accordingly, they do not include all of the information and footnotes
required by accounting principles generally accepted in the United States for
complete financial statements. In the opinion of management, all adjustments
(consisting of normal recurring entries) considered necessary for a fair
presentation have been included. Operating results for the three and nine
months ended September 30, 2005, are not necessarily indicative of the results
that may be expected for the full year ending December 31, 2005.  It is
suggested that these condensed consolidated financial statements be read in
conjunction with the consolidated financial statements and notes thereto
included in the Company's Annual Report for the year ended December 31, 2004.

Principles of Consolidation

eGene's financial statements include the accounts of its wholly owned
subsidiary BioCal Technology, Inc. All significant inter-company balances and
transactions have been eliminated in consolidation.

2.  UNREGISTERED SALES OF EQUITY SECURITIES

The following stock options were exercised in the first quarter of 2005.

Udo Henseler                 1/31/2005             103,333 shares
Rolf Kojima                  2/16/2005              11,667 shares
Ming S. Liu                  3/16/2005              96,667 shares

          * These securities were sold under Rule 506 of Regulation D of the
            Securities and Exchange Commission and Section 4(2) of the
            Securities Act of 1933, as amended.  All purchasers were either
            "accredited investors" or directors, officers or affiliates of our
            Company.
<PAGE>                          6
                           eGene, Inc.

      NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                         September 30, 2005

                          (Unaudited)

During the three months ended September 30, 2005, we received $400,000 from
"accredited investors" as deposit for future private placement subscription of
"restricted securities" while the private placement subscription documents
were still pending in the negotiation process. As of the date of this 10-QSB
Quarterly Report, we have not yet finalized the private placement subscription
documents for the deposit.

3. STOCK-BASED COMPENSATION

eGene accounts for its stock options and equity awards under the intrinsic
value method in accordance with the provisions of Accounting Principles Board
Opinion No. 25, "Accounting for Stock Issued to Employees", and related
interpretations, and has elected to follow the "disclosure only" alternative
prescribed by Financial Accounting Standards Board's SFAS No. 123, "Accounting
for Stock-Based Compensation".  Accordingly, no compensation expense is
recognized in eGene's financial statements for stock options granted to
employees, which had an exercise price equal to the fair value of the
underlying common stock on date of grant.  eGene accounts for stock options
listed to non-employees in accordance with the provisions of SFAS No. 123 and
EITF No. 96-18, "Accounting for Equity Instruments that are issued to other
than Employees for Acquiring or in Conjunction with selling Goods or
Services".

The following table illustrates the effect on net loss and net loss per share
if eGene had applied the fair value recognition provisions of SFAS No.
123, as amended by SFAS No. 148, "Accounting for Stock-Based Compensation-
Transition and Disclosure- and amendment of FASB Statement No. 123."  For
purposes of pro forma disclosures, the estimated fair value of the options is
amortized to expense over the vesting period of the options using the
straight-line allocation method.  eGene's pro forma information is as follows:

              Three Months Ended September 30, Nine Months Ended September 30,
                            2005       2004            2005          2004
Net loss, as reported   $(209,783)  $(249,361)     $(700,731)     $(857,395)

Compensation cost under
fair value-based accounting
method, net of tax          1,387          92          2,833            803

Net loss, pro forma      (211,170)   (249,453)      (703,564)      (858,198)

Net loss per common share
Basic and Diluted
As reported             $   (0.01)   $  (0.02)     $   (0.04)    $    (0.08)

Pro forma                   (0.01)      (0.02)         (0.05)         (0.08)

Weighted average shares 15,624,188  12,833,305     15,584,446     11,197,406

The fair value under FAS 123 for options and equity awards granted were
estimated at the date of grant using a Black-Scholes option pricing model with
the following weighted average assumptions:

            Expected life (years)       5-8
            Interest rate                 3%
            Volatility                    0%
            Dividend yield                0%
<PAGE>                          7
                           eGene, Inc.

      NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                         September 30, 2005

                          (Unaudited)

4.  INVENTORIES

Inventories are stated at the lower of cost or market.  Inventories at
September 30, 2005 consisted of the following:
                                                 September 30,
                                                     2005

           Finished goods                        $      60,500
           Raw materials                               252,408
                                                 -------------
           Total                                 $     312,908
                                                 =============
5.  SUBSEQUENT EVENTS

On October 18, the company announced that it has signed a collaboration
agreement with Professor Andras Guttman, Marie Curie Chair of the European
Commission, the head of the Horvath Laboratory of Bioseparation Sciences in
the University in Innsbruck, Austria. This collaboration agreement will allow
eGene to work closer with Professor Guttman's laboratory on more genetic
testing including haplotyping. The study was also supported by the Austrian
Genome program (GenAu), the Hungarian Ministry of Health and Education
(Szent-Gyorgyi Program), and the European Commission (Marie Curie Actions). A
healthy population of 100 individuals of Hungarian origin was investigated for
genotype frequencies for two important polymorphisms in the deoxycytidine
Kinase. Since 2004, the company has shipped over 100 units of high-performance
genetic analyzer (HDA-GT12(TM))to research laboratories worldwide. These
instruments are being currently used for a wide variety of applications
including microsatellite analysis, restriction digest sample quality checks as
well as oligonucleotide quality checks.

On October 26 to 28, the company exhibited at the American Society of Human
Genetics Conference (ASHG) in the Salt Palace Convention Center at Salt Lake
City. eGene attended this meeting to introduce the company and products to the
people in human genetics society. Live demonstrations were conducted with the
HDA-GT12(TM) system during this conference so people could experience the
differences between traditional genetic analysis method and our automated
system.

6.  FUTURE PRIVATE PLACEMENT SUBSCRIPTION OF RESTRICTED SECURITIES
During the three months ended September 30, 2005, we received $400,000 from
"accredited investors" as deposit for future private placement subscription of
"restricted securities" while the private placement subscription documents
were still pending in the negotiation process. As of the date of this 10-QSB
Quarterly Report, we have not finalized the private placement subscription
documents for the deposit.

We also have an additional $201,000 in a simultaneous private placement that
is being held in escrow by our legal counsel that is subject to receipt of
minimum funding of $250,000, exclusive of the aforesaid $400,000.

7.  RELATED PARTY TRANSACTIONS

During the three months ended September 30, 2005, we purchased parts from a
manufacturing company, whose ownership includes one of our directors and
shareholders.  The total purchases were $14,359.  The total balance owed to
this party as of September 30, 2005 was $14,359.

During the three months ended September 30, 2005, we received $14,198 in
product sales from a shareholder. The party's accounts receivable balance as
of September 30, 2005 was $4,212.
<PAGE>                          8
Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations.

This Management's Discussion and Analysis of Financial Condition and Results
of Operations as of September 30, 2005, and for the three and nine month
periods ended September 30, 2005 and 2004, should be read in conjunction with
our financial statements included in our 10-KSB Annual Report for the year
ended December 31, 2004, that was filed with the Securities and Exchange
Commission on April 15, 2005 (the "2004 10-KSB Annual Report").

Statements made in this 10-QSB Quarterly Report which are not purely
historical are forward-looking statements with respect to our goals, plan
objectives, intentions, expectations, financial condition, results of
operations, future performance and business, including, without limitation,
(i) our ability to raise capital, and (ii) statements preceded by, followed by
or that include the words "may," "would," "could," "should," "expects,"
"projects," "anticipates," "believes," "estimates," "plans," "intends,"
"targets" or similar expressions.  Forward-looking statements involve inherent
risks and uncertainties, and important factors (many of which are beyond our
Company's control) that could cause actual results to differ materially from
those set forth in the forward-looking statements, including the following,
general economic or industry conditions, nationally and/or in the communities
in which we conduct business, changes in the interest rate environment,
legislation or regulatory requirements, conditions of the securities markets,
our ability to raise capital, changes in accounting principles, policies or
guidelines, financial or political instability, acts of war or terrorism,
other economic, competitive, governmental, regulatory and technical factors
affecting our operations, products, services and prices.
<PAGE>                          9
Accordingly, results actually achieved may differ materially from expected
results in these statements. Forward-looking statements speak only as of the
date they are made. We do not undertake, and specifically disclaim, any
obligation to update any forward-looking statements to reflect events or
circumstances occurring after the date of such statements.

Executive Summary.

Business.

Currently, genetic analyses performed in most research and application
laboratories use traditional slab-gel electrophoresis systems, a technology
which was developed more than 20 years ago and has not seen a major face-lift
since its inception. The slab-gel method is labor intensive and time
consuming.  A new replacement technology is expected to be developed for
current genetic analyses.

eGene believes the answer lies in a high-throughput and high-performance
automated genetic analysis system. Such systems can take many forms, whether
they involve instrumentation, reagent and software configuration - but they
must be affordable and acceptable for routine analysis.

Therefore, eGene has designed a reliable genetic analysis system based on the
micro-channel concept of capillary electrophoresis. Our systems provides
automated, affordable, rapid and accurate quantitative genetic analysis,
especially for polymerase chain reaction (PCR) amplified DNA products, which
represents a large segment of the genetic analysis market.

We believe the usage of the high-throughput and low-cost HDA-GT12  system will
remove the high-cost genetic service barrier and stimulate a greater demand
for low-cost genetic analysis tools. More users are expected to enter the
genetic analysis business.

Our HDA-GT12 (High-Performance Genetic Analyzer) system detects, quantifies,
identifies and characterizes biological organisms. It advances and automates
many routine and non-routine genetic laboratory and industrial procedures that
include, but are not limited to, new and improved production methods, enhanced
and novel product development opportunities, quality control, security,
genetic identity, paternity, crime, bioterrorism, pathogen detection, drug
monitoring, safety methods and overall productivity.

We are developing three channels to distribute our complete system solutions
to customers: Distributing directly to customers, distributing indirectly
through our international network of distributors and distributing through
our developing original equipment manufacturer ("OEM") channels. Our OEM
distribution channel enables us to extend the commercial potential of our
advanced technologies into new industries and new applications with
experienced commercial partners. In the OEM channel, we plan to provide our
enabling technologies to potential commercial partners who will then integrate
the application solution and market them to their end customers.
<PAGE>                          10
Critical Accounting Policies, Estimates and Assumptions.

We consider our accounting policies related to revenue recognition, inventory
reserve and warranty accrual to be critical. Inherent in our determination of
when to recognize revenue, and in our calculation of our inventory reserve and
warranty accrual, are a number of significant estimates, assumptions and
judgments. These include deciding whether the elements required to recognize
revenue from a particular arrangement are present and estimating the amount of
inventory obsolescence and warranty costs associated with shipped products. We
base our estimates and judgments on historical experience and on various other
assumptions that we believe to be reasonable under the circumstances. Actual
results could differ materially from these estimates. There have been no
material changes to our critical accounting policies since we filed our 2004
Annual Report on Form 10-KSB with the Securities and Exchange Commission. For
a description of our critical accounting policies, please refer to our 2004
Annual Report on Form 10-KSB.

Third Quarter Overview.

During the third quarter of 2005, our sales decreased $59,471, or 21%, from
sales of $283,026 in the third quarter of 2004. This decrease in our quarterly
sales reflects the fluctuation in some of our distribution channels.

During the third quarter of 2005, U.S. Patent Office has issued to us two
patents: U.S. Pat. No. 6929779 titled "Optical detection in bio-separation
device using axial radiation output on August 16 and U.S. Pat. No. 6932940
titled "Optical detection in bio-separation device using axial radiation
input" on August 23.

Severe new equity funding delays are creating material commercial success
uncertainties for us. Our accompanying financial statements have been prepared
assuming we will continue as a going concern. However, as discussed in Note 2
to our audited financial statements of our year ended December 31, 2004, that
are contained in the 2004 10-KSB Annual Report, we have accumulated losses and
are still developing our planned principal operations. These factors and
ongoing delays in new funding raise doubt about our ability to continue as a
going concern. Our financial statements do not include any adjustments that
might result from the outcome of this uncertainty.

We have limited financial resources and our operations from inception through
September 30, 2005, have been unprofitable. We are still commencing our
planned principal operations and seeking increased capital funding. If we are
unsuccessful in our efforts and cannot attain sufficient profitable operations
or if we cannot obtain additional sources of funding or investments, we may
substantially curtail or terminate our operations.

At a meeting held on July 19, 2005, our Board of Directors voted to remove Dr.
Udo Henseler as Chief Executive Officer (CEO) of our Company and to replace
him with Ming S. Liu, all effective as of that date. On July 20, 2005, Jeffrey
S. Williams resigned as our Chief Financial Officer, effective as of that
date. As of the date of this 10-QSB Quarterly Report, we have not filled the
vacancy left by Mr. Williams' resignation.  We are negotiating the final
outcome of future payments to be made to our former CEO, the outcome of which
cannot be reasonably determined at this time. As of September 30, 2005, we
have accrued for all accrued wages and vacation due to our former CEO,
amounting to $111,790.

<PAGE>                          11
Results of Operations.

Revenue.

Total sales decreased for the three months ended September 30, 2005, as
compared to the same period in 2004. Our sales decreased $59,471, or 21% from
sales of $283,026 in the third quarter of 2004. This decrease in our quarterly
sales reflects the fluctuation in some of our distribution channels. The major
sale decrease in the third quarter of 2005 was within Japan market. It was
mainly due to government budget delay according to our distributor. During the
third quarter of 2005, we observed the sale activities increase in Europe and
Asia as compared to the same period in 2004.

                   Three Months Ended
                        September 30,

                    2005      2004       $change   %change 2004

Total Revenues     $223,555  $283,026    ($59,471)    (21%)

Cost of Sales.

In addition to our goal of attaining more sustainable revenue growth, we are
continuing to focus on improving our gross margins and controlling product
costs by working with cost effective global sourcing partners.

Expenses.

Total expenses for the quarter ended September 30, 2005, were $326,747, which
was $91,177 lower as compared to the same period in 2004.

The major expense decreases were for legal expenses and professional fees
related to merger activities in 2004.

We expect to devote additional expense resources to substantially
strengthening and broadening our marketing and sales infrastructure, and for
other general corporate activities.

Selling and marketing expenses are expected to increase primarily due to
planned amplified sales that require augments in personnel costs related to
our initial and future growth related construction of our marketing, sales and
service functions, and general increases in other marketing and sales support
initiatives. We expect selling, marketing and product promotion expenses to
grow over the next several years to support a more global commercialization of
our products.

The net loss for the quarter ended September 30, 2005, was $209,783, which was
$39,578 lower compared to the previous year's quarterly loss of $249,361.

Liquidity and Capital Resources.

Our cash and cash equivalents were $250,186 at September 30, 2005, compared to
$833,766 at September 30, 2004.

We have financed our operations primarily through equity sales and initial
product sales and services. The inclusion of BioCal operations after July 14,
2004, had a significant impact on our business and the comparability of cash
flows on a period-over-period basis.

Related Transactions.

During the three months ended September 30, 2005, we purchased parts from a
manufacturing company, whose ownership includes one of our directors and
shareholders. The total purchases were $14,359. The total balance owed to
this party as of September 30, 2005 was $14,359.
<PAGE>                          12
During the three months ended September 30, 2005, we received $14,198 in
product sales from a shareholder. The party's accounts receivable balance as
of September 30, 2005 was $4,212.

Cash Flows.

                                   Three Months Ended
                                         September 30,
                                     2005       2004        $change

Net Cash provided (used)
by operating activities       $(225,989)     $(822,894)     $596,905

Cash Flows from
investing activities            $(7,708)      $(29,550)      $21,842

Cash Flows from
Financing activities           $400,000     $1,521,956   $(1,121,956)

Operating Activities.

During the three months ended September 30, 2005, we used $225,989 of cash for
operating activities as compared to $822,894 of cash used in the same period
of 2004.

Investing Activities.

Investing activities during the three months ended September 30, 2005, were
$2,657 for purchase of fixed assets and $5,051 for additional costs incurred
for deferred patent legal fees and additional facility deposit.

Financing Activities.

During the three months ended September 30, 2005, we received $400,000 from
"accredited investors" as deposit for future private placement subscription of
"restricted securities" while the private placement subscription documents
were still pending in the negotiation process. As of the date of this 10-QSB
Quarterly Report, we have not finalized the private placement subscription
documents for the deposit.

If, however, our current in-progress private placement of "restricted
securities" to "accredited investors" only is successful and we achieve the
revenues to be derived from our commercial sales of our products, our cash
balances will be sufficient to fund our operations at least through 2005.

Our actual cash needs could vary considerably depending upon how successful we
are in our efforts to obtain additional sources of funding or investments,
opportunities and commercial uncertainties that may arise over the course of
the remaining period of 2005 and the full year 2006. During or after this
period, if cash generated by operations is insufficient to satisfy our
liquidity requirements, we may need to sell additional equity or debt
securities or obtain additional credit arrangements. An inability to obtain
additional financing may force delays in R&D, marketing and sales activities
and, ultimately, cause us to cease operations.

In the future, we may seek additional funds to support our strategic business
needs and may seek to raise such additional funds through private or public
sales of securities, strategic relationships, bank debt, lease financing
arrangements or other available means. If additional funds are raised through
the issuance of equity or equity-related securities, stockholders may
experience additional dilution, or such equity securities may have rights,
preferences or privileges senior to those of the holders of our common stock.
<PAGE>                          13
Going Concern Qualification of our Auditors.

Our accompanying financial statements have been prepared assuming we will
continue as a going concern. We have accumulated losses and are still
developing our planned principal operations. These factors raise substantial
doubt about our ability to continue as a going concern. Management's plans in
regard to these matters are also described in Note 2 of our audited financial
statements that are contained in our 2004 10-KSB Annual Report. These
financial statements do not include any adjustments that might result from the
outcome of this uncertainty.

Item 3. Controls and Procedures.

We have evaluated our "disclosure controls and procedures" and our "internal
controls and procedures for financial reporting" as of September 30, 2005.
This evaluation was done under the supervision and with the participation of
management.

Evaluation of Disclosure Controls and Procedures.

Regulations under the Securities Exchange Act of 1934 require public
companies, including our company, to evaluate any change in our "internal
control over financial reporting," which is defined as a process to provide
reasonable assurance regarding the reliability of financial reporting and
preparation of financial statements for external purposes in accordance with
accounting principles generally accepted in the United States. In connection
with our evaluation of our disclosure controls and procedures as of the end of
the period covered by this Quarterly Report, our Chief Executive Officer,
Executive VPs and Business Manager did not identify any change in our internal
control over financial reporting during the three months ended September 30,
2005 that materially affected, or is reasonably likely to materially affect,
our internal control over financial reporting. Disclosure controls are
designed with the objective of ensuring that information is accumulated and
communicated to our management, as appropriate to allow timely decisions
regarding required disclosure. It should be noted though that eGene is a young
and emerging biotechnology company with limited resources, funding and
personnel, and that our evaluation of controls and procedures were conducted
in good faith considering the economic environment of our Company.

Changes in Internal Controls.

Internal controls over financial reporting are procedures which are designed
with the objective of providing reasonable assurance that: (1) our
transactions are properly authorized; (2) our assets are safeguarded against
unauthorized or improper use; and (3) our transactions are properly recorded
and reported, all to permit the preparation of our financial statements in
conformity with accounting principles generally accepted in the United States.
Among other matters, we evaluated our internal controls over financial
reporting to determine whether there were any "significant deficiencies" or
"material weaknesses," and sought to determine whether we have identified any
acts of fraud involving personnel who have a significant role in eGene's
internal controls. In the professional auditing literature, "significant
deficiencies" may be interpreted as being comparable as "reportable
conditions"; these are control issues that could have a significant adverse
effect on the ability to record, process, summarize, and report financial data
in the financial statements. A "material weakness" is defined in the auditing
literature as a particularly serious reportable condition where the internal
control does not reduce to a relatively low level the risk that misstatements
caused by error or fraud may occur in amounts that would be material in
relation to the financial statements and would not be detected within a timely
period by employees in the normal course of performing their assigned
functions.
<PAGE>                          14
There were no material changes in our internal controls over financial
reporting during the quarter ended September 30, 2005, that have materially
affected, or are reasonably likely to materially affect, our internal control
over financial reporting.

Consistent with Section 10A(i)(2) of the Securities Exchange Act of 1934, as
added by Section 202 of the Sarbanes-Oxley Act of 2003, we are responsible for
listing the non-audit services approved by our Chief Executive Officer to be
performed by Mantyla McReynolds LLC, our independent auditor. Non-audit
services are defined as services other than those provided in connection with
an audit or a review of our financial statements.

Limitations on the Effectiveness of Controls.

Our management does not expect that our disclosure controls or our internal
controls will prevent all error and all fraud. A control system can provide
only reasonable, not absolute, assurance that the objectives of the control
system are met. Further, the design of a control system must reflect the fact
that there are resource constraints, and the benefits of controls must be
considered relative to their costs. Because of the inherent limitations in all
control systems, no evaluation of controls can provide absolute assurance that
all control issues and instances of fraud, if any, within our Company have
been detected. These inherent limitations include the realities that judgments
in decision-making can be faulty, and that breakdowns can occur because of
simple error or mistake. Additionally, controls can be circumvented by the
individual acts of some persons, by collusion of two or more people or by
management override of the control. Because of the inherent limitations in a
cost-effective control system, misstatements due to error or fraud may occur
and not be detected.

                   Part II Other Information

Item 1. Legal Proceedings.

None; not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the three months ended September 30, 2005, we received $400,000 from
"accredited investors" as deposit for future private placement subscription of
"restricted securities" while the private placement subscription documents
were still pending in the negotiation process. As of the date of this 10-QSB
Quarterly Report, we have not yet finalized the private placement subscription
documents for the deposit.

We also have an additional $201,000 in a simultaneous private placement that
is being held in escrow by our legal counsel that is subject to receipt of
minimum funding of $250,000, exclusive of the aforesaid $400,000.

Item 3. Defaults Upon Senior Securities.

None; not applicable.

Item 4. Submission of Matters to a Vote of Security Holders.

None; not applicable.

Item 5. Other Information.

At a meeting held on July 19, 2005, our Board of Directors of eGene voted to
remove Dr. Udo Henseler as Chief Executive Officer (CEO) of our Company and to
replace him with Ming S. Liu, all effective as of that date. On July 20, 2005,
Jeffrey S. Williams resigned as our Chief Financial Officer, effective as
of that date. As of the date of this 10-QSB Quarterly Report, we have not
filled the vacancy left by Mr. Williams' resignation.  We are negotiating the
final outcome of future payments to be made to the former CEO, the outcome of
which cannot be reasonably determined at this time.  As of September 30, 2005,
we have accrued for all accrued wages and vacation due to the former CEO,
amounting to $111,790.

Item 6. Exhibits.

Exhibits:

31.1 302 Certification of Ming S. Liu

32 906 Certification

                          SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Quarterly Report to be signed on its behalf by
the undersigned, thereunto duly authorized.

                                eGene, Inc.



Dated: November 14, 2005        By:  /s/ Ming S. Liu
                                Ming S. Liu
                                Chief Executive Officer, Executive
                                Vice President and Director

<PAGE>                          15